<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235079</url>
  </required_header>
  <id_info>
    <org_study_id>DCASL30501-4</org_study_id>
    <secondary_id>EUDRACT number 2005-001570-28</secondary_id>
    <nct_id>NCT00235079</nct_id>
  </id_info>
  <brief_title>Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment.</brief_title>
  <acronym>CORP 2</acronym>
  <official_title>Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP 2 Trial: COlchicine for Recurrent Pericarditis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria Locale 3, Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Sanitaria Locale 3, Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether colchicine is safe and effective in
      treatment and prevention of recurrent pericarditis after failure of conventional treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colchicine is safe and effective in the management of recurrent pericarditis after failure of
      conventional treatment. Preliminary data (observational, non-randomized studies without a
      control group) have shown that the drug may be effective in treatment of the second and
      subsequent recurrence and the prevention of further recurrences.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence rate at 18 months</measure>
    <time_frame>18 m onths</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom persistence at 72 hours, remission rate at 1 week. Disease-related re-hospitalization, cardiac tamponade, constrictive pericarditis within the duration of the study.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Pericarditis</condition>
  <condition>Recurrence</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5mg BID (&gt;70Kg) or 0.5 once daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0.5mg BID (&gt;70Kg) or 0.5 once daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.5mg BID (&gt;70Kg) or 0.5 once daily for 6 months</description>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the second and subsequent attack of recurrent pericarditis,

          -  Ageâ‰¥ 18 years,

          -  Informed consent.

        Exclusion Criteria:

          -  Suspected neoplastic, tuberculous, or purulent etiology,

          -  Known severe liver disease and/or elevated transaminases &gt;1.5 times the upper limit of
             normality,

          -  serum creatinine&gt;2.5 mg/dl,

          -  Serum CK over the upper limit of normality or Known myopathy,

          -  Known gastrointestinal or blood disease,

          -  Pregnant or lactating women or women not protected by a contraception method,

          -  Known hypersensibility to colchicine,

          -  Treatment with colchicine at the enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Imazio, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department. Maria Vittoria Hospital. ASL 3 Torino (Coordinating Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rita Trinchero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology Department. Maria Vittoria Hospital. ASL 3 Torino (Coordinating Center).</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rivoli</name>
      <address>
        <city>Rivoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology Department. Maria Vittoria Hospital ASL3 Torino (Coordinating Center)</name>
      <address>
        <city>Torino</city>
        <zip>10141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Imazio M, Cecchi E, Ierna S, Trinchero R; CORP Investigators. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials--two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale. J Cardiovasc Med (Hagerstown). 2007 Oct;8(10):830-4.</citation>
    <PMID>17885522</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2005</study_first_submitted>
  <study_first_submitted_qc>October 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pericarditis</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Therapeutics</keyword>
  <keyword>Prevention</keyword>
  <keyword>Colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Pericarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

